Renvela 800 mg Tablets: SmPC Summary
Quick summary: Renvela 800 mg film-coated tablets contain sevelamer carbonate and are used to help manage high phosphate levels in people with chronic kidney disease, including those on dialysis. This page summarises the SmPC-style...
This content is for educational purposes only and does not replace medical advice, diagnosis or treatment from a qualified healthcare professional.
Quick summary: Renvela 800 mg film-coated tablets contain sevelamer carbonate and are used to help manage high phosphate levels in people with chronic kidney disease, including those on dialysis. This page summarises the SmPC-style information in a clear, practical format.
Key points: taken with meals, phosphate levels are monitored regularly, and the tablet should be used exactly as prescribed in the official product information.
Medical disclaimer: This article is for general information only and does not replace the official SmPC, patient leaflet, or advice from a doctor or pharmacist. It does not provide personal medical advice, diagnosis, or treatment decisions.
What Renvela 800 mg tablets are used for
Renvela 800 mg film-coated tablets are used to help control hyperphosphataemia in adults with chronic kidney disease, including patients on dialysis. The medicine helps reduce the amount of phosphate absorbed from food.
The original content also notes use in children over 6 years old with similar phosphate control needs. For paediatric use, the official product information should always be checked carefully.
How Renvela works
Renvela contains sevelamer carbonate. It works in the gut by binding dietary phosphate, which helps prevent phosphate from being absorbed into the bloodstream.
This phosphate-binding action is why Renvela is used as part of phosphate management in chronic kidney disease.
Dosage and administration
The current content states that the usual total daily dose may range from 2.4 g to 4.8 g daily, given in three divided doses with meals. The dose may be adjusted according to serum phosphate levels.
Phosphate levels are typically monitored regularly, and the dose may be reviewed every 2 to 4 weeks based on response. Exact dosing should always follow the official SmPC and the prescriber’s instructions.
Because this medicine is taken with meals, timing and adherence matter. If a patient is unsure how to take it, the pharmacist or prescriber should be consulted.
Possible side effects
The content highlights common gastrointestinal side effects, including:
- nausea
- vomiting
- constipation
More serious concerns mentioned in the source include gastrointestinal obstruction. Symptoms such as abdominal pain, severe constipation, or bloating should be assessed promptly by a healthcare professional.
The source also notes that sevelamer may bind fat-soluble vitamins, so vitamin status may need to be reviewed by the clinical team.
Who should not use Renvela
According to the source content, Renvela should not be used in people with:
- known hypersensitivity to sevelamer or any ingredient in the tablet
- bowel obstruction
- hypophosphataemia
The original text also flags swallowing difficulties as an important practical concern. If a patient cannot swallow tablets whole, the official product information and a healthcare professional should be consulted.
Storage information
Renvela tablets should be stored in a cool, dry place, away from direct sunlight and moisture. They should be kept out of reach of children and pets.
Always check the expiry date and follow the storage instructions in the pack leaflet or carton.
Practical points for pharmacists and patients
For safe use, the key points to verify are the indication, the prescribed dose, meal timing, and the latest phosphate results. The official SmPC should also be checked for any product-specific instructions.
If there are concerns about gastrointestinal symptoms, swallowing, or vitamin monitoring, these should be reviewed by the prescriber or pharmacist using the official product information.
Frequently asked questions
▸ What is Renvela 800 mg?
Renvela 800 mg is a film-coated tablet containing sevelamer carbonate. It is used to help manage high phosphate levels in people with chronic kidney disease.
▸ What type of medicine is Renvela?
Renvela is a phosphate binder. It works in the digestive tract to reduce phosphate absorption from food.
▸ How is Renvela usually taken?
The source content states that it is usually taken in divided doses with meals. The exact regimen should follow the official SmPC and the prescriber’s instructions.
▸ What side effects are mentioned in the source?
Nausea, vomiting, constipation, and possible gastrointestinal obstruction are mentioned. Any concerning symptoms should be reviewed promptly by a healthcare professional.
▸ Can Renvela affect vitamins?
The source notes that it may bind fat-soluble vitamins. Vitamin monitoring or supplementation should only be considered under clinical guidance.
▸ Who makes Renvela?
The source identifies Genzyme Corporation, a Sanofi subsidiary, as the manufacturer.
Safety reminder: If a patient has severe constipation, abdominal pain, bloating, swallowing problems, or any unexpected reaction, they should seek medical advice promptly and refer to the official product leaflet or SmPC.
Medical disclaimer
This content is for educational purposes only. It should not be used as a substitute for professional medical advice, diagnosis or treatment. Always ask a doctor, pharmacist or qualified healthcare professional before starting, stopping or changing any medicine.
Sources and verification
The following sources or official references are listed to support verification of the medicine information discussed in this article.
Medicine information can change and may vary depending on country, product formulation, patient history and professional guidance. Always check official medicine information and ask a healthcare professional for personal medical questions.